Business Context and Reporting Period
Company: Standard BioTools Inc. (Nasdaq: LAB)
Filing Type: Form 10-K (Annual Report)
Period: Fiscal Year Ended December 31, 2025
Business Overview: Standard BioTools provides life science tools for proteomics and genomics, including the CyTOF, Hyperion, and Biomark platforms. The company operates as a single reportable segment following a strategic reassessment in early 2025.
Major Transaction: On June 22, 2025, the company entered into an agreement to sell its SomaScan Business (SomaLogic and Sengenics) to Illumina, Inc. The transaction closed on January 30, 2026. The SomaScan Business is classified as a discontinued operation in this filing.
Key Financial Metrics (Fiscal Year 2025)
| Metric | 2025 Value | 2024 Value |
|---|---|---|
| Total Revenue | $85.3 million | $91.0 million |
| Gross Profit | $42.5 million | $44.9 million |
| Gross Margin | 50.0% | 49.3% |
| Net Loss (Continuing Ops) | ($58.8 million) | ($90.9 million) |
| Net Loss (Total) | ($74.9 million) | ($138.9 million) |
| Cash & Equivalents | $120.9 million | $166.7 million |
| Total Investments | $92.4 million | $126.1 million |
| Working Capital | $346.0 million | N/A |
| Debt | None material (Convertible notes: $0.3M) | None material |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 6% to $85.3 million, driven by a $4.3 million drop in consumables revenue due to macroeconomic pressures and a $1.9 million decrease in services revenue.
- Operating Expenses: Total operating expenses decreased 11% to $152.8 million. This was primarily due to a $25.8 million reduction in transaction and integration expenses (related to the 2024 SomaLogic merger) and a $2.8 million decrease in R&D expenses.
- Restructuring Costs: Restructuring charges increased 18% to $14.8 million, reflecting severance costs from workforce reductions impacting approximately 20% of the global workforce.
- Income Tax Benefit: The company recorded a significant income tax benefit of $37.9 million (vs. $0.5 million expense in 2024), driven by a partial release of the valuation allowance on deferred tax assets based on the expected gain from the SomaScan sale.
- Discontinued Operations: The SomaScan Business generated $101.3 million in revenue but resulted in a net loss of $16.1 million for the year.
Guidance, Outlook, and Risks
Management Commentary:
- Strategic Focus: The company is consolidating R&D capabilities in Singapore and relocating its headquarters to Boston to improve operational efficiency.
- Liquidity: Management expects existing cash and investments ($187.6 million total) to be sufficient to fund operations for at least the next 12 months.
- Transaction Impact: The sale of the SomaScan Business is expected to generate a pre-tax gain recognized in Q1 2026, with total consideration of up to $425 million (including earn-outs).
Key Risks and Contingencies:
- Profitability: The company has incurred losses since inception with an accumulated deficit of $1.3 billion and may continue to incur losses.
- Legal Proceedings: Pending shareholder litigation regarding the SomaLogic merger (trial scheduled for March 2027) and a dispute with Shareholder Representative Services regarding Palamedrix milestone payments (potential exposure up to $17.5 million).
- Supply Chain: Reliance on sole-source suppliers for critical components (e.g., electron multiplier detectors, specific metals) poses operational risks.
- Regulatory: Products are labeled "Research Use Only" (RUO); any shift to clinical diagnostic use would require FDA clearance, which is uncertain and costly.
Investor Verification Checklist
- SomaScan Sale Closing: Verify the final closing date (Jan 30, 2026) and the actual cash consideration received versus the projected $350 million upfront payment.
- Valuation Allowance Release: Confirm the realization of the $38.4 million tax benefit release in Q1 2026 financials contingent on the SomaScan sale gain.
- Restructuring Completion: Monitor the execution of the 20% workforce reduction and the associated cost savings in future quarters.
- Legal Outcomes: Track the status of the Delaware Court of Chancery litigation regarding the SomaLogic merger and the Palamedrix milestone dispute.
- Consumables Trend: Assess whether the decline in consumables revenue stabilizes as the installed base grows and macroeconomic pressures ease.